Dr. John Lister-James, Ph.D. serves as Vice President of Chemical Development and Manufacturing at Avid Radiopharmaceuticals, Inc. Dr. Lister-James has over 20 years of experience in research and development in the pharmaceutical industry, principally in the area of radiopharmaceuticals. He served as Vice President of Development at Xanthus Pharmaceuticals, Inc. since May 22, 2006. Dr. Lister-James joined Xanthus from the Schering AG group, where he served as Vice President of Corporate CMC Development of Radiopharmaceuticals, at CIS-US, Inc. and was responsible for Corporate Chemistry, Manufacturing and Controls (CMC) Development of radiopharmaceuticals. He was responsible for Research, CMC and Nonclinical Development and Clinical Research at Diatide Research Laboratories, a division of Berlex Laboratories (also a subsidiary of Schering AG). He served as Vice President of Science and Technology at Diatide, Inc. While at Diatide, he directed CMC/Nonclinical Development leading to the regulatory approval of NeoTect(R)/NeoSpect(TM) and AcuTect(R), and directed R&D activities leading to the discovery and early development of NeoTide(TM). Earlier, he held technical and management positions at Centocor, where he supervised research and development of radiolabeled monoclonal antibodies.

Radiopharmaceuticals